Fifth Third Bancorp
FITB
$54.40
+0.39%
Fifth Third Bancorp is a Cincinnati-headquartered regional bank with roughly $300 billion in total assets, providing retail and commercial banking, card and treasury management, wealth and asset management, and capital markets services across a Midwest core and an expanding Southeast footprint. The bank sits in the upper tier of U.S. regional banks and has repositioned itself as a consolidator rather than a consolidat-ee, closing its acquisition of Comerica in February 2026 to create a top-10 U.S. bank with meaningful Texas deposit density. The investor narrative is now dominated by integration execution: the market is debating whether Fifth Third can deliver the promised cost synergies and cross-sell revenue while absorbing a larger, lower-margin balance sheet, and the Q1 2026 earnings trough followed by a sharp Q2-Q3 recovery has become the central proof point. Recent coverage from The Motley Fool and Investing.com frames the story as a faster-than-expected Comerica integration with strong Texas deposit growth, positioning FITB as a structural share gainer rather than a simple rate-sensitive lender.…
FITB
Fifth Third Bancorp
$54.40
Related headlines
Investment Opinion: Should I buy FITB Today?
Rating: Buy. Fifth Third is a post-merger re-rating story where the fundamentals have already caught up to the price: Q3 2026 revenue of $4.506 billion grew 36.55% year-over-year, net margin recovered to 19.22% from 4.27% in Q1, and Q3 EPS of $0.91 fully matched the pre-deal Q3 2025 figure on a 36.5% larger revenue base. With 18 of 21 analysts at Buy, zero Sells, and an average target of $61.54 implying 16.0% upside from $53.04 — and even the $55.00 low target 3.7% above the market — the published research range is uniformly above the current price.
The supporting evidence is broad: the forward PE of 10.68x sits 19% below the 13.19x trailing multiple, implying the market already discounts consensus 2027 EPS of $5.42; the PEG of 1.07 prices that growth at roughly fair value; ROE of 11.61% and ROA of 0.997% are at or above the regional bank benchmark; TTM free cash flow of $2.775 billion against a $31.1 billion market cap implies an ~8.9% FCF yield; and the 3.74% dividend yield with a well-covered 46.1% payout ratio provides a total-return floor. Price-to-book of 1.43x is a modest premium to book, consistent with an ROE above 11%.
The biggest risks that could invalidate the thesis are (1) integration slippage — the Q1 2026 trough of $0.16 EPS and 4.27% net margin shows how severely charges can distort results, and quarterly FCF swung from -$1.252 billion to $2.622 billion; (2) deposit competition compressing the net interest margin that underpins the 19.22% net margin; and (3) multiple compression from 1.43x P/B back toward the 1.23x-1.31x range of 2023-2024. This Buy would upgrade to a high-conviction Buy if ROA pushes meaningfully above 1.0% on realized cost synergies or the stock clears $59.50 resistance, and would downgrade to Hold if 2027 EPS estimates fall below $5.00 or P/B exceeds 1.6x without matching ROE improvement. Verdict: fairly valued to modestly undervalued on forward earnings, with the premium P/B the main constraint on upside.
Sign up to view all
FITB 12-Month Price Forecast
The forward view is constructive but not euphoric: the fundamentals have clearly inflected — Q3 EPS of $0.91 matched pre-deal levels on a 36.5% larger revenue base — yet at 1.43x book and 13.19x trailing earnings the market has already awarded FITB credit for a successful Comerica integration, so the margin of safety is thinner than the 16.0% average analyst upside suggests. The 10.68x forward PE and 1.07 PEG provide the clearest valuation support, and the 3.74% dividend yield with a 46.1% payout ratio gives a total-return floor that limits downside. The key swing factor is whether cost synergies push ROA meaningfully above the current 0.997% benchmark; if they do, the stock re-rates toward the $67 high target, but if integration costs persist or deposit competition compresses margins, the premium P/B leaves roughly 23% downside to the $40.68 52-week low. I would upgrade to high confidence on a decisive break above $59.50 or a quarter with net margin above 20%, and downgrade to neutral if 2027 EPS estimates fall below $5.00 or the stock breaks below the $47.17 May base.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Fifth Third Bancorp's 12-month outlook, with a consensus price target around $61.54 and implied upside of +13.1% versus the current price.
Average Target
$61.54
22 analysts
Implied Upside
+13.1%
vs. current price
Analyst Count
22
covering this stock
Price Range
$55 - $67
Analyst target range
Coverage is broad and overwhelmingly constructive: 21 analysts cover FITB with 18 Buy ratings, 4 Hold, and 0 Sell, producing a consensus recommendation of "buy" and a recommendation mean of 1.55 (where 1.0 is a strong buy). The average target price of $61.54 implies roughly 16.0% upside from the current $53.04, and even the lowest target of $55.00 sits 3.7% above the current price — meaning the entire published range is above the market, an unusually bullish configuration that signals analysts view the recent pullback as a buying opportunity rather than a warning.
The target range of $55.00 to $67.00 is moderately wide (about 22% spread from low to high), reflecting genuine uncertainty over Comerica synergy timing rather than disagreement on direction. The $67.00 high target likely assumes full cost-synergy realization, continued Texas deposit growth, and multiple expansion toward 1.6x-1.7x book, while the $55.00 low target prices in slower integration, margin compression from deposit competition, and a more muted EPS trajectory. Institutional ratings show a clear upgrade bias — Citigroup moved from Neutral to Buy on September 22, Evercore ISI upgraded from In Line to Outperform on October 21, and JP Morgan, RBC, UBS, and Truist have all reiterated Buy/Overweight/Outperform ratings through October — a pattern of positive estimate revisions that typically precedes target-price increases and supports the bullish consensus.
Bulls vs Bears: FITB Investment Factors
The bull case currently holds the stronger evidence: revenue is up 36.55% year-over-year, net margin has recovered from 4.27% to 19.22%, EPS has fully matched pre-deal levels, and all 21 analysts have targets above the current price with a 16.0% average upside. The bear case rests less on fundamentals than on price — at 1.43x book and 13.19x trailing earnings, the market has already awarded FITB credit for a successful Comerica integration, so the margin of safety is thinner than the analyst consensus implies. The single most important tension is whether the promised cost synergies can push ROA meaningfully above the current 0.997% benchmark; if they do, the forward PE of 10.68x looks cheap and the stock re-rates toward the $67 high target, but if integration costs persist or deposit competition compresses margins, the premium P/B leaves 20%+ downside to the 52-week low. Near term, the technical picture is a recovery from an August-September drawdown rather than a confirmed breakout, so the resolution of the $58.00-$59.50 resistance zone will be the first real test of whether the fundamental re-rating has legs.
Bullish
- Analyst consensus uniformly above market: All 21 covering analysts rate FITB Buy or Hold with zero Sells, and the lowest target of $55.00 sits 3.7% above the current $53.04 — meaning even the bear case in published research implies upside. The $61.54 average target implies 16.0% upside, an unusually bullish configuration that frames the recent pullback as opportunity.
- Comerica integration driving revenue inflection: Q3 2026 revenue of $4.506 billion grew 36.55% year-over-year from $3.300 billion, with sequential acceleration from $3.867 billion in Q1 to $4.431 billion in Q2. Q3 EPS of $0.91 fully matched pre-deal Q3 2025 EPS despite a 36.5% larger revenue base, showing dilution is being worked through faster than feared.
- Profitability fully restored from integration trough: Net margin recovered to 19.22% in Q3 from just 4.27% in Q1, and operating margin of 24.59% is essentially back to the pre-deal 25.36% level on a much larger balance sheet. Gross margin improved to 70.06% from 63.76% a year ago, evidence that cost synergies are landing.
- Attractive forward valuation and dividend floor: At 10.68x forward earnings versus 13.19x trailing, the market is pricing 19% EPS growth, consistent with consensus 2027 EPS of $5.42. The 3.74% dividend yield — well above the typical 2.5-3.0% regional bank range — with a well-covered 46.1% payout ratio provides total-return support and a valuation floor.
Bearish
- Valuation already prices in successful integration: At 1.43x price-to-book — near the 1.45x Q4 2024 peak and above the 1.23x-1.31x levels of 2023-2024 — and 13.19x trailing PE in the upper-middle of its normalized 11x-14x band, FITB is no longer a deep-value bank trade. Further re-rating requires EPS beats or multiple expansion, leaving little cushion for disappointment.
- Earnings volatility from integration costs: The Q1 2026 integration quarter saw EPS collapse to $0.16 and net income of just $165 million, a 4.27% net margin, versus $0.91 EPS in Q3. Quarterly free cash flow swung from -$1.252 billion in Q1 to $2.622 billion in Q2, showing how lumpy the integration period remains.
- Mediocre returns versus peers: ROE of 11.61% and ROA of 0.997% are merely at the industry benchmark rather than exceptional, meaning the bank earns only par returns on a now much larger asset base. Without further margin expansion from cost synergies, the profitability case for a premium multiple is thin.
- Recent momentum is a recovery, not a breakout: Despite the 5.83% one-month gain, FITB is still down 7.09% over three months and lagged SPY by 2.18 points over that period, reflecting the 14.5% peak-to-trough slide from $58.06 on August 14 to $49.64 on October 14. Volume of 6.45 million shares is unremarkable, so the bounce is unconfirmed until it clears the $58.00-$59.50 resistance zone.
FITB Technical Analysis
FITB is in a sustained, if choppy, uptrend: the stock is up 24.68% over the past year and 11.17% year-to-date, and at $53.04 it sits at roughly 65.6% of its 52-week range of $40.68 to $59.50. That positioning is constructive but not euphoric — the shares are about 10.9% below the 52-week high, meaning the stock has room to run before hitting overextension territory, while the 52-week low is a full 23.3% below current levels, confirming a rising floor. The trend structure (higher lows from the May 2026 base near $47) supports a buy-the-dip posture rather than a momentum-chasing one.
Short-term momentum has re-accelerated sharply and is now diverging positively from the medium-term trend: the stock is up 5.83% over the past month versus a 7.09% decline over three months, a swing of nearly 13 percentage points that signals a trend reversal attempt rather than a dead-cat bounce. The relative strength data confirms this — FITB outperformed SPY by 10.82 percentage points over one month (SPY fell 4.99% while FITB rose), yet it lagged by 2.18 points over three months, so the recent move is a recovery from an August-September drawdown (from $58.06 on August 14 to $49.64 on October 14, a 14.5% peak-to-trough slide) rather than fresh breakout momentum. Volume of 6.45 million shares is unremarkable, and the absence of RSI data means the 5.8% one-month pop should be treated as unconfirmed until it clears the October highs.
Key technical levels are well defined: resistance sits at the $58.00-$59.50 zone (the August highs and 52-week high), and a decisive break above $59.50 would confirm the post-Comerica re-rating and open blue-sky territory, while support rests at the $49.64 October low and then the $47.17 May base, with a break below $47 signaling the integration thesis is losing credibility. The stock's beta of 0.989 means it moves roughly in line with the market — notably low for a regional bank, which reduces position-sizing risk but also caps the torque available from a sector rotation. The maximum drawdown of -21.21% over the period is moderate for a bank stock and suggests the market has already absorbed a meaningful de-risking event, leaving asymmetric upside if the $59.50 resistance gives way.
Beta
0.99
0.99x market volatility
Max Drawdown
-21.2%
Largest decline past year
52-Week Range
$41-$60
Price range past year
Annual Return
+26.5%
Cumulative gain past year
| Period | FITB Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | -2.4% |
| 3m | -6.1% | -2.3% |
| 6m | +14.9% | +2.8% |
| 1y | +26.5% | +11.3% |
| ytd | +14.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
FITB Fundamental Analysis
Revenue is inflecting sharply upward on the back of the Comerica deal: Q3 2026 revenue hit $4.506 billion, up 36.55% year-over-year from $3.300 billion in Q3 2025, and up sequentially from $4.431 billion in Q2 and $3.867 billion in Q1. The multi-quarter arc shows the acquisition closing in February 2026 (Q1 revenue $3.867 billion, EPS just $0.16) followed by two consecutive quarters of strong expansion, with Q3 EPS of $0.91 matching the pre-deal Q3 2025 level despite a 36.5% larger revenue base — evidence that dilution is being worked through. Segment data (Commercial Banking $222 million, Branch Banking $158 million, Wealth & Asset Management $2 million) is reported on a narrow basis and understates the consolidated picture, but the commercial franchise is clearly the growth engine, consistent with the Texas deposit expansion narrative.
Profitability has recovered decisively from the integration trough: Q3 2026 net income was $866 million with a net margin of 19.22%, up from $165 million and a 4.27% margin in Q1, and gross margin improved to 70.06% from 67.29% in Q1 and 63.76% in Q3 2025. The operating margin of 24.59% in Q3 compares favorably to 5.35% in Q1 and 25.36% in the pre-deal Q3 2025, showing the bank has essentially restored its pre-acquisition profitability ratio on a much larger base. ROE of 11.61% and ROA of 0.997% are respectable but not exceptional for a regional bank — ROA near 1.0% is the industry benchmark, so FITB is at par, and further margin expansion from cost synergies is the key lever for upside.
Balance sheet and cash flow metrics are solid but require context: debt-to-equity of 0.668 is moderate for a bank, the current ratio of 0.821 reflects the liability-heavy structure typical of depositories, and TTM free cash flow of $2.775 billion against a $31.1 billion market cap implies an FCF yield of roughly 8.9% — attractive, though quarterly FCF is highly volatile ($651 million in Q3, $2.622 billion in Q2, -$1.252 billion in Q1). The Q3 cash flow statement shows $3.925 billion of debt repayment alongside $403 million of dividends paid, and the 3.74% dividend yield with a 46.1% payout ratio is well covered by earnings. The company is generating enough internal capital to fund operations and return cash, but the heavy investment-securities churn ($4.839 billion of purchases in Q3) means balance-sheet management, not external financing dependence, is the real swing factor.
Quarterly Revenue
$4.5B
2026-09
Revenue YoY Growth
+36.5%
YoY Comparison
Gross Margin
70.1%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is FITB Overvalued?
Because Fifth Third is solidly profitable (Q3 net income of $866 million, positive trailing EPS), the PE ratio is the appropriate primary metric. The stock trades at 13.19x trailing earnings but only 10.68x forward earnings — a 19% compression that implies the market expects meaningful EPS growth, consistent with consensus 2027 EPS of $5.42 versus the current run-rate. The PEG ratio of 1.07 suggests the growth is being priced at roughly fair value, neither a bargain nor a stretch.
Against the regional bank sector, FITB's 13.19x trailing PE and 1.43x price-to-book look reasonable rather than cheap: a P/B near 1.4x is a modest premium to book, typical for a bank with ROE above 11%, while the 2.42x price-to-sales and 11.19x EV/EBITDA reflect the revenue base expansion from Comerica. The 3.74% dividend yield is a meaningful support for total return and sits well above the sector's typical 2.5-3.0% range, offering a valuation floor that pure multiple comparison misses. On balance, the stock screens as fairly valued to slightly inexpensive relative to its own profitability, with the forward PE gap providing the clearest margin of safety.
Historically, FITB's PE has ranged from roughly 7.0x (Q3 2023) to 72.6x (the distorted Q1 2026 integration quarter), with a more normal band of 11x-14x over the past two years; the current 13.19x sits near the upper-middle of that normalized range, while the P/B of 1.43x is close to the 1.45x Q4 2024 peak and above the 1.23x-1.31x levels seen through 2023-2024. That positioning suggests the market is already pricing in successful integration and synergy realization — the stock is not a deep-value bank trade anymore, and further re-rating requires either EPS beats or multiple expansion from a lower-rate, higher-fee environment.
PE
13.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~17x
vs. Industry Avg
12.0x
Industry PE ~12.0x*
EV/EBITDA
11.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the Comerica integration and the balance sheet it created. The Q1 2026 trough — EPS of $0.16, net income of $165 million, and a 4.27% net margin — demonstrates how severely integration charges can distort earnings, and quarterly free cash flow swung from -$1.252 billion in Q1 to $2.622 billion in Q2, showing the lumpiness is not resolved. ROA of 0.997% sits right at the industry benchmark, so the bank has no profitability cushion if cost synergies slip, and the current ratio of 0.821 plus debt-to-equity of 0.668 reflect a liability-heavy structure where $3.925 billion of Q3 debt repayment and $4.839 billion of investment-securities purchases make balance-sheet management the real swing factor. Revenue concentration in the newly acquired Texas and commercial franchise adds execution risk: the commercial banking segment is the growth engine, and any deposit attrition or cross-sell shortfall there would hit the consolidated numbers directly.
Market and competitive risks are dominated by valuation compression. At 1.43x price-to-book — near the 1.45x Q4 2024 peak and above the 1.23x-1.31x range of 2023-2024 — and 13.19x trailing PE in the upper-middle of its normalized 11x-14x band, FITB has already been awarded credit for successful integration, so any disappointment invites multiple contraction rather than just estimate cuts. Deposit competition and a lower-rate environment threaten the net interest margin that underpins the 19.22% net margin, while the 3.74% dividend yield, though supportive, is a cost that constrains reinvestment. A beta of 0.989 means the stock offers little diversification from broad market moves, and the recent news flow — while positive on Texas deposit growth — frames the story entirely around integration execution, leaving little room for a negative surprise without a sharp re-rating.
The worst-case scenario is a stalled integration: cost synergies arrive a year late, Texas deposit growth decelerates, and margin compression from deposit competition forces analysts to cut the $5.42 2027 EPS estimate, compressing the multiple back toward the 11x low end of its range. In that chain, the stock would retest the $49.64 October low and then the $47.17 May base, with a break below $47 signaling the thesis has lost credibility and opening the path toward the $40.68 52-week low — roughly 23% below the current $53.04. The -21.21% maximum drawdown already recorded shows this magnitude of decline is realistic for this name, and the $55.00 analyst low target offers only a 3.7% cushion, meaning the published bear case does not fully capture a genuine integration failure.
FAQ
Ranked by severity: first, integration execution risk — the Q1 2026 quarter produced EPS of just $0.16 and a 4.27% net margin, and quarterly free cash flow swung from -$1.252 billion in Q1 to $2.622 billion in Q2, so recurring charges would hit earnings hard. Second, valuation compression — at 1.43x book and 13.19x trailing PE in the upper-middle of its 11x-14x band, disappointment invites multiple contraction, not just estimate cuts, with a return toward 1.23x-1.31x book implying meaningful downside. Third, margin and deposit competition — the 19.22% net margin depends on a stable net interest margin, and a lower-rate environment or aggressive deposit pricing would erode it. Fourth, company-specific profitability risk — ROA of 0.997% is only at the industry benchmark, leaving no cushion if cost synergies slip, and the -21.21% maximum drawdown shows the stock can de-rate sharply.
The base case carries 50% probability with a $58.00-$62.00 target range, assuming net margin holds in the 18%-20% band, operating margin stays near 24.6%, and EPS tracks toward the $5.42 consensus 2027 estimate, letting the stock grind back toward the $61.54 analyst average. The bull case at 30% probability targets $63.00-$67.00, driven by full cost-synergy realization lifting ROA above the 0.997% benchmark, Texas deposit growth, and multiple expansion toward 1.6x-1.7x book, approaching the $67.00 high target. The bear case at 20% probability targets $47.00-$55.00, where late synergies and margin compression force 2027 EPS cuts and a retest of the $49.64 October low and $47.17 May base. The base case is most likely, and its key assumption is that integration charges do not recur beyond the Q1 2026 trough already absorbed.
The answer depends on which multiple you weight. On forward earnings the stock looks modestly undervalued: 10.68x forward PE against 13.19x trailing implies the market is discounting roughly 19% EPS growth, consistent with the consensus 2027 estimate of $5.42, and the 1.07 PEG prices that growth at about fair value. On book value it looks closer to fully valued: 1.43x price-to-book is near the 1.45x Q4 2024 peak and above the 1.23x-1.31x range of 2023-2024, a premium justified only if ROE (currently 11.61%) improves. The 2.42x price-to-sales and 11.19x EV/EBITDA reflect the enlarged post-Comerica revenue base rather than a stretched multiple. Net verdict: fairly valued to modestly undervalued, with the forward PE gap as the main margin of safety and the premium P/B as the main constraint.
On a risk/reward basis the setup is favorable but not one-sided. The average analyst target of $61.54 implies 16.0% upside from $53.04, and unusually, even the lowest target of $55.00 sits 3.7% above the current price, with 18 Buy ratings and zero Sells across 21 analysts. Valuation support comes from a 10.68x forward PE versus 13.19x trailing, a 1.07 PEG, and a 3.74% dividend yield covered by a 46.1% payout ratio. The offset is that at 1.43x book the market has already priced a successful Comerica integration, and the realistic downside to the $40.68 52-week low is roughly 23%. It is a good buy for patient total-return investors comfortable with integration execution risk; it is less attractive for anyone needing near-term certainty, given the stock is still down 7.09% over three months.
The profile favors a medium-to-long holding period rather than short-term trading. The 3.74% dividend yield with a 46.1% payout ratio rewards patience and provides a total-return floor, while the 0.989 beta means the stock offers little short-term torque relative to the market — it moves roughly in line with the index, so there is limited trading edge from macro swings. Earnings visibility is improving but still lumpy: quarterly EPS moved from $0.16 to $0.84 to $0.91 across 2026, and free cash flow swung by nearly $3.9 billion between Q1 and Q2, which argues against tight tactical positioning around prints. A concrete minimum holding period of 12-18 months allows the Comerica cost synergies to fully annualize and gives the stock time to work through the $58.00-$59.50 resistance zone. Short-term traders should note the defined levels — $49.64 and $47.17 on the downside, $59.50 on the upside — but the dividend and integration thesis are best expressed with a longer horizon.